Oropharyngeal Carcinoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Amplification
ABL1 Fusion
ABL1 Mutation
BRAF
BRAF Amplification
BRAF Mutation
CDKN2A Expression
CDKN2A No Expression
CDKN2A Overexpression
DDR2
DDR2 Amplification
DDR2 Mutation
EGFR
EGFR Amplification
EGFR Mutation
EPHA2
EPHA2 Amplification
EPHA2 Mutation
ERBB2

ERBB2 Amplification
ERBB2 Mutation
ERBB4
ERBB4 Amplification
ERBB4 Loss
ERBB4 Mutation
FGFR1
FGFR1 Amplification
FGFR1 Fusion
FGFR1 Mutation

FGFR2
FGFR2 Amplification
FGFR2 Fusion
FGFR2 Mutation
FLT1
FLT1 Amplification
FLT1 Mutation
FLT4
FLT4 Amplification
FLT4 Mutation

FRK
FRK Mutation
HLA-A*02 Positive
HLA-A*02:01 Positive
HPV Negative
HPV Positive
KDR
KDR Amplification
KDR Mutation
KIT

KIT Amplification
KIT Fusion
KIT Mutation
MAPK11
MAPK11 Amplification
MAPK11 Mutation
PD-L1 Expression (CPS >= 1)
PDGFRA
PDGFRA Amplification
PDGFRA Fusion

PDGFRA Mutation
PDGFRB
PDGFRB Amplification
PDGFRB Fusion
PDGFRB Mutation
RAF1
RAF1 Amplification
RAF1 Mutation
RET
RET Amplification

RET Fusion
RET Mutation
TEK
TEK Mutation
TRNAK2
TRNAK2 Mutation
VEGFA
VEGFA Amplification
VEGFB
VEGFB Amplification

VEGFC
VEGFC Amplification

Overview

Oropharyngeal carcinomas most frequently harbor alterations in TP53, PIK3CA, KMT2D, CDKN2A, and NOTCH1 [2].

Most Commonly Altered Genes in Oropharyngeal Carcinoma

TP53 Mutation, PIK3CA Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KMT2D Mutation are the most common alterations in oropharyngeal carcinoma [2].

Top Alterations in Oropharyngeal Carcinoma

Clinical Trials

View Clinical Trials for Oropharyngeal Carcinoma

There are 23 clinical trials for oropharyngeal carcinoma, of which 17 are open and 6 are completed or closed. Of the trials that contain oropharyngeal carcinoma as an inclusion criterion, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 2 are no phase specified (1 open).

CDKN2A, HPV, and HLA-A*02 are the most frequent gene inclusion criteria for oropharyngeal carcinoma clinical trials [3].

Trials Investigating Oropharyngeal Carcinoma by Gene and Recruiting Status

Bintrafusp alfa, intensity-modulated radiation therapy, and dpx-e7 hpv vaccine are the most common interventions in oropharyngeal carcinoma clinical trials.

Drugs Being Investigated in Oropharyngeal Carcinoma Trials by Recruiting Status

Significant Genes in Oropharyngeal Carcinoma

ABL1 +

ABL1 is altered in 0.75% of oropharyngeal carcinoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is altered in 1.07% of oropharyngeal carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is altered in 3.07% of oropharyngeal carcinoma patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is altered in 4.04% of oropharyngeal carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is altered in 3.6% of oropharyngeal carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is altered in 3.96% of oropharyngeal carcinoma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is altered in 1.89% of oropharyngeal carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 2.17% of oropharyngeal carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is altered in 2.72% of oropharyngeal carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is altered in 2.41% of oropharyngeal carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is altered in 2.21% of oropharyngeal carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is altered in 1.84% of oropharyngeal carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is altered in 1.42% of oropharyngeal carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is altered in 1.61% of oropharyngeal carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is altered in 0.39% of oropharyngeal carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is altered in 2.89% of oropharyngeal carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is altered in 1.4% of oropharyngeal carcinoma patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is altered in 0.68% of oropharyngeal carcinoma patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Malignant Oropharyngeal Neoplasm

Children

Tonsillar Carcinoma and Oropharyngeal Squamous Cell Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Oropharyngeal Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Oropharyngeal Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types